Greenwich LifeSciences, Inc.
GLSI
$11.67
-$0.26-2.18%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 132.03% | 117.99% | 87.79% | 4.70% | -17.77% |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 72.16% | 74.12% | 71.66% | 14.67% | 13.71% |
Operating Income | -72.16% | -74.12% | -71.66% | -14.67% | -13.71% |
Income Before Tax | -76.08% | -79.37% | -77.57% | -17.45% | -15.30% |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -76.08% | -79.37% | -77.57% | -17.45% | -15.30% |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -76.08% | -79.37% | -77.57% | -17.45% | -15.30% |
EBIT | -72.16% | -74.12% | -71.66% | -14.67% | -13.71% |
EBITDA | -72.19% | -74.15% | -71.68% | -14.68% | -13.72% |
EPS Basic | -71.60% | -75.80% | -74.67% | -15.49% | -13.96% |
Normalized Basic EPS | -71.65% | -75.81% | -74.68% | -15.47% | -13.91% |
EPS Diluted | -71.60% | -75.80% | -74.67% | -15.49% | -13.96% |
Normalized Diluted EPS | -71.65% | -75.81% | -74.68% | -15.47% | -13.91% |
Average Basic Shares Outstanding | 2.66% | 1.88% | 1.29% | 1.49% | 0.96% |
Average Diluted Shares Outstanding | 2.66% | 1.88% | 1.29% | 1.49% | 0.96% |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |